What happened
FDA states that, through the International Coalition of Medicines Regulatory Authorities Collaborative Assessment Pilot, it and regulators from Australia, Canada, Japan, Switzerland, and the European Medicines Agency jointly assessed a recombinant endotoxins testing approach for biological products. The method is an alternative to the horseshoe crab blood-dependent Limulus Amebocyte Lysate test. The submission used a Post-Approval Change Management Protocol covering several biological products across multiple therapy areas. The European Medicines Agency led the review, and the PACMP was approved in June 2026, with participating authorities reaching aligned decisions within days. FDA says the pilot coordinates questions and reviews while preserving independent decisions, aiming to improve consistency, reduce duplication, and support timely access.
Why it matters
For pharmaceutical manufacturers, the update may matter because endotoxin testing is described as a critical safety and quality step for biological products. The assessed recombinant method could reduce dependence on animal-derived test materials while maintaining product-quality oversight. The PACMP and coordinated review model may also offer a pathway for proposing certain post-approval manufacturing changes across participating jurisdictions with more consistent questions, less duplicative regulatory work, and improved review predictability; each authority nevertheless makes its own decision.
Key topics: Recombinant endotoxins testing for biological products, Post-Approval Change Management Protocol approval, ICMRA Collaborative Assessment Pilot